コンテンツへスキップ
Merck
  • Electrotransfection and lipofection show comparable efficiency for in vitro gene delivery of primary human myoblasts.

Electrotransfection and lipofection show comparable efficiency for in vitro gene delivery of primary human myoblasts.

The Journal of membrane biology (2014-12-24)
Tomaz Mars, Marusa Strazisar, Katarina Mis, Nejc Kotnik, Katarina Pegan, Jasna Lojk, Zoran Grubic, Mojca Pavlin
要旨

Transfection of primary human myoblasts offers the possibility to study mechanisms that are important for muscle regeneration and gene therapy of muscle disease. Cultured human myoblasts were selected here because muscle cells still proliferate at this developmental stage, which might have several advantages in gene therapy. Gene therapy is one of the most sought-after tools in modern medicine. Its progress is, however, limited due to the lack of suitable gene transfer techniques. To obtain better insight into the transfection potential of the presently used techniques, two non-viral transfection methods--lipofection and electroporation--were compared. The parameters that can influence transfection efficiency and cell viability were systematically approached and compared. Cultured myoblasts were transfected with the pEGFP-N1 plasmid either using Lipofectamine 2000 or with electroporation. Various combinations for the preparation of the lipoplexes and the electroporation media, and for the pulsing protocols, were tested and compared. Transfection efficiency and cell viability were inversely proportional for both approaches. The appropriate ratio of Lipofectamine and plasmid DNA provides optimal conditions for lipofection, while for electroporation, RPMI medium and a pulsing protocol using eight pulses of 2 ms at E = 0.8 kV/cm proved to be the optimal combination. The transfection efficiencies for the optimal lipofection and optimal electrotransfection protocols were similar (32 vs. 32.5%, respectively). Both of these methods are effective for transfection of primary human myoblasts; however, electroporation might be advantageous for in vivo application to skeletal muscle.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
リン酸カリウム 一塩基性, ACS reagent, ≥99.0%
Sigma-Aldrich
リン酸カリウム 二塩基性, ACS reagent, ≥98%
Sigma-Aldrich
リン酸カリウム 一塩基性, powder, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99.0%
Sigma-Aldrich
リン酸カリウム 一塩基性, buffer substance, anhydrous, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., 99.5-100.5%
Sigma-Aldrich
リン酸カリウム 二塩基性, puriss. p.a., ACS reagent, anhydrous, ≥99.0% (T)
Sigma-Aldrich
L-グルタチオン、還元型, suitable for cell culture, BioReagent, ≥98.0%, powder
Sigma-Aldrich
リン酸カリウム 一塩基性, for molecular biology, ≥98.0%
Sigma-Aldrich
リン酸カリウム 一塩基性, meets analytical specification of Ph. Eur., NF, E340, anhydrous, 98-100.5% (calc. to the dried substance)
Sigma-Aldrich
リン酸カリウム 二塩基性, anhydrous, for luminescence, for molecular biology, BioUltra, ≥99.0% (T)
Sigma-Aldrich
L-グルタチオン、還元型, ≥98.0%
Sigma-Aldrich
リン酸カリウム 二塩基性 溶液, 1.0 M
Sigma-Aldrich
リン酸カリウム 一塩基性, ReagentPlus®
Sigma-Aldrich
リン酸カリウム 二塩基性, reagent grade, ≥98.0%
Sigma-Aldrich
リン酸カリウム 一塩基性, BioUltra, for molecular biology, anhydrous, ≥99.5% (T)
Sigma-Aldrich
リン酸カリウム 一塩基性, 99.99% trace metals basis
Supelco
グルタチオン, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
リン酸カリウム 二塩基性, 99.95% trace metals basis
Sigma-Aldrich
リン酸カリウム 一塩基性, JIS special grade, ≥99.0%
Sigma-Aldrich
L-グルタチオン、還元型, BioXtra, ≥98.0%
USP
一塩基性リン酸カリウム, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Potassium phosphate dibasic, meets USP testing specifications
Supelco
リン酸カリウム 一塩基性, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
リン酸カリウム 一塩基性, tested according to Ph. Eur., anhydrous
L-グルタチオン、還元型, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
リン酸カリウム 一塩基性, SAJ first grade, ≥99.0%
Sigma-Aldrich
リン酸カリウム 二塩基性, JIS special grade, ≥99.0%
Sigma-Aldrich
リン酸カリウム 一塩基性, ≥99.5%
Sigma-Aldrich
リン酸カリウム 二塩基性, SAJ first grade, ≥98.0%